Overview

Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Alzheimer's Dementia

Status:
Recruiting
Trial end date:
2022-01-11
Target enrollment:
Participant gender:
Summary
This is an open label, eight week, clinical trial of a proprietary high CBD/low THC sublingual solution for the treatment of clinically significant anxiety and agitation in mild to moderate Alzheimer's Disease.
Phase:
Early Phase 1
Details
Lead Sponsor:
Mclean Hospital
Collaborator:
Spier Family Foundation
Treatments:
Pharmaceutical Solutions